Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.

Saved in:
Bibliographic Details
Title: Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
Authors: Lloyd KA; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Parsons BN; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Burkitt MD; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Moore AR; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom; Liverpool University Hospitals, National Health Service Foundation Trust, Liverpool, United Kingdom., Papoutsopoulou S; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Boyce M; Trio Medicines, Ltd, Hammersmith Medicines Research, London, United Kingdom., Duckworth CA; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Exarchou K; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom; Liverpool University Hospitals, National Health Service Foundation Trust, Liverpool, United Kingdom., Howes N; Liverpool University Hospitals, National Health Service Foundation Trust, Liverpool, United Kingdom., Rainbow L; Centre for Genomic Research, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom., Fang Y; Centre for Genomic Research, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom., Oxvig C; Department of Molecular Biology and Genetics, Aarhus University, Aarhus C, Denmark., Dodd S; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Varro A; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Hall N; Centre for Genomic Research, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom; The Earlham Institute, Norwich, Norfolk, United Kingdom; School of Biological Sciences, University of East Anglia, Norwich, Norfolk, United Kingdom., Pritchard DM; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom; Liverpool University Hospitals, National Health Service Foundation Trust, Liverpool, United Kingdom. Electronic address: mark.pritchard@liv.ac.uk.
Source: Cellular and molecular gastroenterology and hepatology [Cell Mol Gastroenterol Hepatol] 2020; Vol. 10 (1), pp. 113-132. Date of Electronic Publication: 2020 Jan 28.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Gastroenterological Association Country of Publication: United States NLM ID: 101648302 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-345X (Electronic) Linking ISSN: 2352345X NLM ISO Abbreviation: Cell Mol Gastroenterol Hepatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-345X
DOI:10.1016/j.jcmgh.2020.01.010